However, despite these variations, CD19 CAR-T therapy has consistently shown high complete remission rates in high-risk, heavily pretreated patients with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL). The gene discussed is CD19; the disease is acute lymphoblastic leukemia.